Trial Profile
Human papillomavirus (HPV) vaccine in human immunodeficiency virus (HIV) positive girls and women
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Therapeutic Use
- 26 Feb 2016 Planned End Date changed from 15 Aug 2013 to 17 Feb 2017 as reported by ISRCTN: Current Controlled Trials record.
- 26 Feb 2016 Status changed from completed to active, no longer recruiting as reported by ISRCTN:Current Controlled Trials record.
- 15 Aug 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.